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esponsibility of ChinAbstract Infected bone defects are normally regarded as contraindications for bone grafting. In the
present study, an antibacterial bone graft substitute was synthesized by loading vancomycin (VCM) in our
previously developed mineralized collagen based composite, nano-hydroxyapatite/collagen/poly (lactic
acid) (nHAC/PLA), aiming to repair large size bone defects and inhibit related infections simultaneously.
The VCM/nHAC/PLA showed typical porous structure with a porosity of (80.776.7)% and compressive
strength of 1.52 MPa. The delivery of VCM from VCM/nHAC/PLA was detected in vitro for up to 4
weeks. And their antibacterial properties were determined using inhibition ratio assay and inhibition zone
assay. Pretty high level of inhibition ratio (more than 99%) was obtained in VCM/nHAC/PLA group.
Additionally, a distinct inhibition zone was clearly formed in Staphylococcus aureus bacterium incubation
dish with VCM/nHAC/PLA disc for up to 18 days of incubation. Moreover, both of the nHAC/PLA
composites with or without VCM exhibited favorable in vitro and in vivo biocompatibilities for rabbitearch Society. Production and hosting by Elsevier B.V. All rights reserved.
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X. Lian et al.550marrow stromal cells (MSCs) adhesion, spreading, proliferation, and triggering no obvious inﬂammation
responses in subcutaneous implantation. Our results suggested that the VCM/nHAC/PLA performed ideal
antibacterial property and biocompatibility and has great promise for the treatment of bone defect-related
infections in orthopedic surgeries.
& 2013 Chinese Materials Research Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Bone defect-related infections (i.e. osteomyelitis) are quite common
in clinic, especially in open bone fracture and trauma, which
seriously affect bone union and are normally regarded as contra-
indications for bone grafting. Conventional treatments such as
surgical debridement and suction–irrigation can only control but
not treat local infections. Therefore, repairing bone defect and
inhibiting related infections synchronously are necessary and
meritorious in clinical treatment. Recently, vancomycin hydrochlor-
ide (VCM HCl), as one of the most commonly used antibiotic
drugs for the treatment of serious, life-threatening infections by
Gram-positive bacteria has been speciﬁcally applied against Sta-
phylococcus aureus in bone defect-related infections treatment.
In clinic, vancomycin is normally given intravenously for systemic
therapy, and the dose levels should be monitored in an effort to
reduce adverse effects such as nephrotoxicity and ototoxicity.
However, relatively high dose of supply is generally imperative in
order to contribute an effective local drug concentration under
systemic administration of antibiotics. Therefore, local drug delivery
systems are thought to be valuable in delivering appropriate local
antibiotic concentration and additionally decreasing the systemic
toxicity and side-effects of parenteral antibiotics [1,2].
It is critical to select an appropriate bone graft substitute to
serve as the drug-loaded vehicle, which should have drug-sustained
release ability and effective ossiﬁcation bioactivity. Among these
popular used bone materials such as poly(methylmethacrylate)
(PMMA), hydroxyapatite bone cement (HAC), and allograft, many
kinds of non-degradable or biodegradable materials have been
used combining with antibiotics in the treatment of S. aureus
induced chronic osteomyelitis. PMMA, as one of the most widely
used bone materials often mixed with antibiotics such as genta-
micin in clinical applications [3,4]. Besides, HAC has also been
reported to mix with vancomycin for the treatment of bone
infections in New Zealand white rabbit tibia [5]. Although it has
been shown that PMMA, hydroxyapatite, and allograft provided
effective local drug concentrations and minimal toxic side-effects
comparing with systemic application [6–9], the non-degradable or
slow-degradable characteristic of these bone materials makes it
difﬁcult to accurately control the kinetic release and period of
antibiotic delivery. Because of these drawbacks, several biode-
gradable and absorbable bone materials such as bioactive borate
glass, calcium sulfate, nano-hydroxyapatite, and biopolymer-based
scaffold have been developed as antibiotic carriers for controlling
bone defect-related infections [10–14].
In our work, a biodegradable bone material, nano-hydroxyapa-
tite/collagen/poly (lactic acid) (nHAC/PLA), was used as antibiotic
carrier to release vancomycin. The nano-hydroxyapatite/collagen/
poly (lactic acid) scaffold was developed previously in our lab
based on mineralized collagen ﬁbrils and showed great potentials
in bone tissue engineering due to its excellent biocompatibility and
biodegradability [15,16]. The mineralized collagen ﬁbrils were
prepared synthetically forming a hierarchically assembled compo-
site that resembled the composition and microstructure of naturalbone [15–19]. Extensive studies have indicated that the nHAC/
PLA scaffold has good osteoconductivity and biodegradablility
and promotes early mineralization and new bone formation
[16,17]. On the histological level, the three-dimensional inter-
connecting porous structure enhances rapid vascularization and
bone tissue invasion, which implies that the nHAC/PLA scaffold
could probably be a promising system to control drug delivery.
In the present study, we constructed a vancomycin-loaded nano-
hydroxyapatite/collagen/poly (lactic acid) bone substitute (VCM/
nHAC/PLA) for repairing bone defects and inhibiting related
infections synchronously. The physicochemical, antibacterial, and
in vitro and in vivo biocompatible properties of the VCM/nHAC/
PLA bone substitute was evaluated and discussed.2. Experimental
2.1. Material preparation and physicochemical properties
characterization
The nHAC powder was prepared as previously reported [15]. The
VCM/nHAC/PLA scaffold was made with similar procedure of
nHAC/PLA composite [15]. In brief, the PLA powder (Shan Dong
Medical Research Institute, China) of molecular weight
100,000 Da was dissolved in dioxane to a ﬁnal concentration of
10% (M/V) and then stirred gently at room temperature for 4–6 h.
The nHAC and the VCM HCl (Eli Lily Japan K.K., Tokyo,
Japan) powders were consecutively added into the stirred PLA
solution at a weight ratio of 1:1:0.1 (nHAC:PLA:VCM HCl) with
around 12 h of interval. After mixed thoroughly, the solution was
poured into a mold, frozen at 20 1C overnight, and then
lyophilized to remove dioxane. The ﬁnal material was sterilized
by 60Co γ-irradiation at the dose of 15 kGy. Control samples
(nHAC/PLA) were also prepared using the same process without
the addition of VCM.
The compositions of two types of bone materials were
characterized by X-ray diffraction (XRD, D/max-2500X) using
monochromated Cu Kα radiation (λ¼1.5405 Å, 120 mA, 40 kV)
in a continuous scan mode with a scanning speed of 81/min, and
the 2θ range was from 101 to 901.
For Fourier transform infrared spectroscopy (FTIR) examination,
the powdered samples were placed onto the diamond window on the
stage of a smart orbit (NICOLET560). The spectra were recorded at a
resolution of 0.35 cm1 and 32 scans with wavenumber from 400 to
4000 cm1.
The porosity of VCM/nHAC/PLA was determined via a liquid
displacement method with isopropyl alcohol (isopropanol,
ρ¼0.784 g/ml). A composite sample with a known weight w0
and volume V was immersed in a beaker holding a volume of
water. A series of brief evacuation-repressurization cycles were
performed to force the liquid into the pores of the sample. Then the
total weight of the water-impregnated sample (w1) was recorded.
The porosity of the composite (ε) is expressed as ε¼ (w1w0)/
ρV 100%.
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samples (three repetitions for each group) were performed in a
Zwick/roell mechanical testing machine equipped with a 10 kN
load cell at a strain rate of 0.5 mm/min. The load was applied until
the sample was compressed to approximately 30% of its original
length. The compressive strength was determined as the maximum
point of the stress–strain curve.
Two groups of composite samples were sputter-coated with
gold ﬁlm for scanning electron microscopy (SEM, QUANTA 200
FEG, Holland) examinations at the voltage of 20 kV.
2.2. In vitro VCM release study
Totally ten VCM/nHAC/PLA cylinders (10 mm in diameter and
20 mm in length) were eluted in 5 ml of standard phosphate buffer
saline (PBS) at 37 1C and pH 7.4. All samples were placed on a
horizontally rotating shaker with 90 rpm at 37 1C. The elution solution
was completely changed every 48 h and stored at 20 1C for subse-
quent measurements. The release of vancomycin was measured over a
period of 4 weeks. VCM release was monitored by measuring the
absorbance of the elution medium at 280 nm using a TU-1901
spectrophotometer according to the calibrating curve (Abs¼4.203
(C) 0.045, C: mg/ml, R¼0.9994) with the ε280 value of VH as a
standard. VCM concentration was determined from the average of
three absorbance readings using the corresponding calibration curve
(0.05–1.0 mg/ml).
The degradation ratio of VCM/nHAC/PLA in PBS after 4 weeks'
incubation was calculated by the formula of η¼ (w0w′)/w′
 100%. W0 and w′ are the weight of the composite before and
after incubation, respectively.
2.3. The antibacterial assay
Antibiotic activity of bone materials against S. aureus (strain
ATCC 9538) was evaluated by inhibition ratio and inhibition zone
assays. The inhibition ratio (R) was calculated according to ASTM
E2149-10 standard test method by the formula as R¼ (AB)/
A 100%, where A is the average number of bacteria after
incubating S. aureus with control sample for 24 h, and B is the
average number of bacteria after incubating S. aureus with test
sample for 24 h.
The inhibition zone assay was performed using the method of
Kirby Bauer test. Brieﬂy, S. aureus bacteria were uniformly
distributed on the surface of the agar plate for bacterial incubation.
All sterilized VCM/nHAC/PLA and nHAC/PLA cylinder samples
(10 mm in diameter and 10 mm in length, ﬁve for each type of
material) were placed in middle of the agar plates and incubated at
37 1C. The inhibition zones forming around the cylinders were
measured by calipers at 24 h. In order to evaluate the long-term
antibiotic effect of the VCM/nHAC/PLA composite, the agar plate
with VCM/nHAC/PLA was incubated up to 18 days and replace
new inoculated plates every three days.
2.4. In vitro and in vivo biocompatibility
Mesenchymal stem cells (MSCs), which have the multipotent capacity
to differentiate into a variety of cell types, including osteoblasts,
chondrocytes, adipocytes, and other connective tissue cells, are widely
used in tissue engineering and regenerative medicine. Rabbit marrow
stromal cells (rMSCs) were isolated from the tibias of 4-month-old
New Zealand white rabbits. Brieﬂy, the rabbit tibia was punctured witha 16-gauge needle after anesthesia and 4–5 ml of bone marrow was
aspirated through a sterile tube into a 10 ml syringe containing 5000
units of heparin. The bone marrow was ﬁltered through a cell strainer,
and the obtained cells were reﬂoated and cultured in growth medium
(GM) containing Dulbecco's modiﬁed Eagle's medium (DMEM;
Gibco, Rockville, MD), 10% (v/v) fetal bovine serum (FBS; Hyclone,
Logan, UT), 100 U/ml penicillin, and 10 mg/ml streptomycin.
Cell growth and adhesion behaviors on the different scaffold
surfaces were examined by SEM observation and proliferation
assay. The two types of composites (nHAC/PLA and VCM/
nHAC/PLA) were cut into small cubes (with dimensions of
5 mm 5 mm 5 mm) for 96-well plate, sterilized by 60Co
γ-irradiation at the dose of 15 kGy. The cells were seeded onto
the sterilized composite at a density of 8000 cells/sample. For
SEM examination (JSM-T300; Jeol, Tokyo, Japan), the composite
samples seeded with cells were collected after 24 h incubation and
then ﬁxed with 2.5% glutaraldehyde in PBS for 0.5 h. After
dehydrated with a series of graded ethanol (30, 50, 70, 80, 90, 95
and 100%), the samples were critical-point dried and then coated
with gold ﬁlm for direct SEM examination. In order to quantita-
tively evaluate cell proliferation, cell counting kit-8 (CCK-8) assay
(Dojindo Molecular Technologies Inc.) was performed according
to manufacturer's protocol. Brieﬂy, after incubating at 37 1C and
5% CO2 for indicated time (1, 3, 5, and 7 days), the culture
medium was replaced with 100 μl fresh medium containing 10 μl
CCK-8 solution in each well for another 3 h incubation before
measurement at 450 nm with a microplate reader (Bio-Rad, Model
680). Four repeated measurements for each time point of each
group (n¼4) were carried out for statistical analysis.
The subcutaneous implantations of these two types of scaffolds
in rabbits for one and three months were performed for evaluating
in vivo biocompatibility. Totally six healthy male adult Japanese
white rabbits were used in this study (average weight was 2.8 kg)
The in vivo study was approved by the ethics committee of School
of Stomatology in China Medical University (2010-01) in She-
nyang and executed according to NIH guidelines for the care and
use of laboratory animals (Animal license No. SCXK (LIAO)
2009-0002). The nHAC/PLA and VCM/nHAC/PLA scaffolds
(5 mm 5 mm 5 mm) were subcutaneously implanted into the
dorsal region of the rabbit. In order to avoid individual differences,
two types of bone substitute samples were transplanted into
different regions of same rabbit for comparison. Brieﬂy, the rabbit
was intravenously anesthetized by 2% pentobarbital sodium
(30 mg/kg) and shaved. Two types of bone materials were
implanted into the regions along the spine with three VCM/
nHAC/PLA scaffolds on one side of the spine and three nHAC/
PLA scaffolds on the other side of the spine. Thus totally six
subcutaneously separate pockets were made in one rabbit by blunt
dissection. The base of the pocket should be more than 10 mm
from the line of incision. Three rabbits were repeated for each time
point (1 or 3 months) contributing to a total of 9 implants for each
sample and each time point. 1 month and 3 months after
implantation, the rabbits were anesthetized, the implanted areas
were dissected, and the implant containing tissues were removed
from the subcutaneous dorsum, ﬁve specimens were made for each
bone material. The samples were ﬁxed in 4% polyformaldehyde
over night and then embedded in parafﬁn, sectioned with 4 μm
each layer and stained with hematoxylin and eosin (H&E) and
Masson's trichrome for histological analysis. This in vivo experi-
ment was repeated two times. Histological evaluation consisted of
a morphological description using a light microscope (BX51;
Olympus).
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All the data were statistically analyzed using SPSS 13.0 software
to express in the standard deviation of the mean. The t-test was
performed and po0.05 was commonly accepted to be statistically
signiﬁcant.3. Results
3.1. Physicochemical properties of vancomycin-loaded bone
substitute
SEM, XRD, and FTIR were used to investigate the microstructure,
crystallinity, and chemical structure of the bone substitute VCM/
nHAC/PLA. Fig. 1 showed the typical comparisons of these
physicochemical properties of the bone materials with and without
vancomycin, which indicated that the involvement of vancomycin
did not signiﬁcantly affect the porous morphologies (Fig. 1(a) and
(b)) and the chemical structures of organic/inorganic compositionsFig. 1 Comparative physicochemical properties of the two types of
morphologies of (a) nHAC/PLA and (b) VCM/nHAC/PLA; (c) XRD anal(Fig. 1(c) and (d)). The porosity of VCM/nHAC/PLA (80.776.7%)
was also similar with that of VCM free sample. And the compressive
strength of VCM/nHAC/PLA (1.5270.09 MPa) has no obvious
difference (p40.05, n¼5) with those of the nHAC/PLA (1.627
0.17 MPa), which was similar with our previous studies [15–19].3.2. In vitro drug release
The kinetic of VCM released from test cylinder samples was
detected over the complete observation period of 4 weeks at 37 1C
and pH 7.4. The VCM release curve was plotted as the released
VCM concentration in PBS as a function of time, as shown in
Fig. 2. The released quantity was initially 0.91470.281 mg/ml
and gradually descended to 0.14970.026 mg/ml at the end of the
observation period (Fig. 2(a)). The cumulative percentages of
antibiotic release from test cylinder sample were about 98% (w/w)
of the calculated total mass of the antibiotic (Fig. 2(b)). The
sustained release of VCM from the VCM/nHAC/PLA composite
may depend on the drug diffusion throughout the matrix bulkbone composite nHAC/PLA and VCM/nHAC/PLA. Typical SEM
ysis; (d) FTIR analysis.
Fig. 2 Sustained release of VCM from standard cylinders of VCM/nHAC/PLA in vitro. (a) Release concentration of VCM; (b) rate of release.
Table 1 Antibiotic activity of material against S. aureus evaluated by inhibition ratio assay.
Sample Average living bacterium number (cfu/ml) Antibacterial
rate (%)
Before shaking After shaking
nHAC/PLA 2.3 104 9.8 104 No antibacterial activity
VCM/nHAC/PLA 2.3 104 o100 499.9
Fig. 3 The typical morphology of the inhibition zone induced by (a) nHAC/PLA and (b)VCM/nHAC/PLA after 72 h of incubation on agar plate.
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the composite after 4 weeks incubation was 11.771.2% (n¼5).
3.3. Antibiotic activity
Antibiotic activity of the VCM-loaded bone material against
S. aureus was evaluated by inhibition ratio and inhibition zone
assays. The inhibition ratio of VCM/nHAC/PLA was more than
99.9% after 24 h incubation, while the pure nHAC/PLA sample
had no any antibacterial effect (as shown in Table 1). The
inhibition zone assay also conﬁrmed the results, as shown in
Fig. 3. The typical morphology of inhibition zone was observed in
the agar plate with VCM/nHAC/PLA sample after 72 h of
incubation with zone size of 21.770.6 mm, while no such
inhibition zone was observed in nHAC/PLA control. In order toevaluate the long-term antibiotic effect of the VCM/nHAC/PLA
composite, the agar plate with VCM/nHAC/PLA was incubated up
to 18 days showing gradually decreased size of the inhibition zone
(Fig. 4). Beyond that, the antibiotic activity of the VCM/nHAC/
PLA sample after 4 weeks of immersion in PBS was also
examined, which still showed obvious antibiotic activity with
1.571.0 mm of inhibition zone size. The result also indicated that
the manufacturing processes of VCM/nHAC/PLA scaffold did not
inﬂuence the antibacterial activity of the antibiotic.
3.4. Biocompatibility evaluation
Interactions between cells and biomaterials offer an effective way
to evaluate in vitro biocompatibility. In this study, rMSCs were
seeded on the top of the scaffolds for cell culture up to one week.
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and nHAC/PLA scaffolds were shown in Fig. 5. rMSCs performed
good cell attachment and spreading on both of the bone materials
with multiple ﬁlopodia. Moreover, CCK-8 assay was used to
quantitatively evaluate cell proliferation of rMSCs on these two
scaffolds, as shown in Fig. 6. No signiﬁcant differences wereFig. 4 The change of inhibition zone size of VCM/nHAC/PLA
during 18 days of incubation.
Fig. 5 The typical SEM morphologies of MSCs on the nHAC/PLA (a)
culture in low and high magniﬁcations.observed between the VCM/nHAC/PLA and nHAC/PLA scaf-
folds, which were in accordance with the SEM results. These
results indicated that the VCM/nHAC/PLA scaffold with 5 wt%
VCM addition had satisﬁed in vitro biocompatibility.
The subcutaneous implantation of the bone materials in rabbits
for 1 and 3 months were performed for evaluating their in vivo
biocompatibility. As shown in Fig. 7, the histology photomicro-
graphs of 1 and 3 months implantation of VCM/nHAC/PLA
composites stained with H&E and Masson showed no obvious
neutrophils and monocytes at the interface between the VCM/
nHAC/PLA and local tissues indicating no signiﬁcant acute
inﬂammatory response initiated by the implants, The VCM/
nHAC/PLA composite possessed satisﬁed in vivo biocompatibil-
ity, which suggested that the VCM-loaded bone composite has
great potential for bone repair and the treatment of bone defect
related infections.4. Discussion
Bone defect-related infections are quite common in clinic, which
seriously affect bone union and recovery. The best treatment is to
control infection and repair bone defect at the same time, which
requires the bone graft composite having good antibacterial
capability with sustained antibiotic release and also osteoinductivity.
Therefore, biodegradable biomaterials have been regarded as anand (b) and VCM/nHAC/PLA (c) and (d) scaffolds after one day cell
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long-term anti-infection. The appropriate porous microstructure
and degradation characteristics make it possible to control the
kinetic property of drug release forming an effective and safe drug
concentration in local tissues. Some previous studies had demon-
strated that prefabricated hydroxyapatite beads impregnated with
gentamicin were effective in eradicating infection in osteomyelitis
[20]. Chen and Chan reported that antibiotic-impregnated auto-
genous bone graft seemed to be an effective and safe method for
the management of small infected tibial defects [21–23]. Our
present study showed the great potential of the involvement of
VCM in our previously developed biomimetic bone material
nHAC/PLA composite for infected bone defect repair.
VCM has already been used for S aureus infection by continuous
infusion. The drug concentration of VCM should be controlled by
therapeutic drug monitoring. It has been proven that high plasma
concentrations of VCM (60–80 μg/ml after 1–2 h by intravenous drip
or a minimum concentration continued to be higher than 30 μg/ml)Fig. 6 Rabbit marrow stromal cells proliferation on the nHAC/PLA
and VCM/nHAC/PLA scaffolds after 1, 3, 5 and 7 days quantitatively
evaluated by CCK-8 assay.
Fig. 7 Histology photomicrographs of subcutaneous implanted bone mate
(c) H&E stained and (d) Masson stained, VCM/nHAC/PLA, 1 month; (e) H
stained (f) Masson stained, VCM/nHAC/PLA, 3 month; scale bar is 100 μwill cause renal failure or ototoxicity according to the operating
instruction manual of VCM HCl (Eli Lily Japan K.K., Tokyo,
Japan). Therefore, less than 10 μg/ml VCM plasma concentration was
recommended in order to prevent renal failure or ototoxicity. In our
study, the initial amount of VCM loaded in the bone scaffold was
determined according to previous publications, our pre-experiments
and clinical data from orthopedic surgeons. For a local drug delivery
system, 5–10 wt% of vancomycin addition was recommended in
clinical research [10,24–26]. The 5 wt% of vancomycin was generally
considered as safe dose for clinical use. We therefore chose 5 wt% of
vancomycin addition in our study.
The bone substitute graft nHAC/PLA was developed based on
biomimetically synthetic mineralized collagen ﬁbrils, which has
been proven to have unique osteoinduction and osteoconducntion
and has been successfully applied for more than tens of thousands
of clinical cases. However, infected bone defects are normally
regarded as contraindications for nHAC/PLA bone grafting. We
therefore developed the drug-loaded nHAC/PLA composite. The
effectiveness and safety are the most important characteristics of the
VCM/nHAC/PLA composite that should be evaluated to ensure its
accurate functions. The VCM/nHAC/PLA scaffold had sustained
release of VCM in 4 weeks that gave the composite a long-term
antibiotic activity, which was probably related to the interconnected
three-dimensional pore structure, high porosity and appropriate
degradation rate. And the in vitro and in vivo biocompatibility
examinations have also proven the safety of released VCM and
good cell proliferation of rMSCs on the scaffolds. Therefore, it can
be concluded that the VCM/nHAC/PLA composite is a biocompa-
tible carrier material for sustained release of VCM and has great
promising for repairing infected bone defects. The effectiveness of
the drug-loaded bone composite in the treatment of S. aureus
induced chronic osteomyelitis was examined in vivo using a rabbit
model, which will be introduced in another paper.5. Conclusion
An antibacterial bone graft substitute was synthesized by loading
antibiotic vancomycin in our previously developed mineralized col-
lagen based composite nHAC/PLA aiming to repair large size bonerials. (a) H&E stained and (b) Masson stained nHAC/PLA, 1 month;
&E stained and (f) Masson stained, HAC/PLA, 3 month; (g) H&E and
m.
X. Lian et al.556defects and inhibit related infections simultaneously. The physico-
chemical properties of the drug-loaded composite VCM/nHAC/PLA
were not affected by the involvement of vancomycin showing
similarity with nHAC/PLA. The drug release assays showed the
long-term sustained release of VCM from the VCM/nHAC/PLA
composite with effective and safe antibacterial ability. And the
involvement of VCM did not affect the in vitro and in vivo
biocompatibilities of the composite, which exhibited satisﬁed biological
security with favorable cell adhesion, spreading, proliferation, and
triggering no obvious inﬂammation responses in subcutaneous implan-
tation. Our results suggested that the VCM/nHAC/PLA bone substitute
performed ideal antibacterial property and biocompatibility and had
great promise for the treatment of bone defect-related infection in
orthopedic surgeries.
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